Key Highlights
- Curaleaf Holdings has publicly disclosed its intention to acquire Aurora Cannabis for US$4.00 per share
- The proposal represents a 45% premium above Aurora’s 30-day volume weighted average trading price of US$2.75
- The transaction structure includes 0.3463 Curaleaf shares combined with US$0.75 in cash for every Aurora share
- Following the announcement, Aurora’s stock price climbed 18%, reaching approximately $4.76 per share
- Aurora’s board rejected two private acquisition approaches from Curaleaf on June 23 and July 7, 2026
In an unexpected move, Curaleaf Holdings has publicly disclosed its acquisition proposal for Aurora Cannabis, valued at US$4.00 per share, following Aurora’s board’s refusal to participate in confidential negotiations.
The announcement triggered a significant market response on Tuesday, with ACB shares climbing more than 18% during trading hours to reach $4.76. Even before the opening bell, pre-market activity showed a 15% increase in the stock price.
Under the proposed transaction terms, Aurora shareholders would receive 0.3463 Curaleaf subordinate voting shares alongside US$0.75 cash per Aurora share held. Using current market valuations, this package equals the stated $4.00 per share offer price.
The proposed acquisition price reflects a substantial 45% premium compared to Aurora’s 30-day volume weighted average of US$2.75. Additionally, it marks a 38% premium relative to Monday’s closing share price.
The offer includes a protective ceiling on the equity component. Should Curaleaf’s shares experience significant appreciation before deal closure, the stock consideration will be limited to ensure total value doesn’t surpass US$5.00 per Aurora share, calculated using Curaleaf’s 20-day VWAP.
According to Curaleaf’s disclosure, the company initially contacted Aurora’s management on June 23, 2026, followed by a second outreach on July 7, 2026. Aurora’s board declined both overtures.
Curaleaf’s CEO Boris Jordan spoke candidly about the rebuff. “We approached Aurora privately and constructively on multiple occasions,” Jordan stated. “We were very disappointed that the Board refused to meaningfully engage.”
Jordan went on to explain that the company would now present the offer directly to Aurora’s shareholder base, characterizing the premium as “compelling” while suggesting continued postponement would be “unjustified.”
Projected Combined Entity Metrics
A merged entity would generate total revenue exceeding US$1.5 billion based on the last twelve months, with adjusted EBITDA approaching US$350 million during the identical timeframe.
Curaleaf projects minimum annual operating synergies of US$40 million resulting from the combination.
Transaction Requirements and Schedule
Currently, no official takeover bid documentation has been submitted. Curaleaf has explicitly stated that the actual offer may not materialize.
The company retains the right to withdraw if unfavorable material information about Aurora emerges during examination, if Aurora implements protective measures, or if Aurora pursues alternative transactions.
Should the formal offer proceed, it would stay open for a 105-day period. Notably, it would not require due diligence clearance or financing approvals, eliminating two frequently encountered obstacles to deal completion.
Complete offer documentation will be submitted to Canadian securities authorities and the U.S. Securities and Exchange Commission when the official bid commences.
Canaccord Genuity has been retained as Curaleaf’s financial advisor for the transaction. Dentons is providing legal representation.
ACB shares closed at $4.76, representing a gain of $0.73, or 18.11%, for the trading session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
